Michael King
Stock Analyst at EF Hutton
(0.82)
# 3,981
Out of 5,090 analysts
109
Total ratings
35.25%
Success rate
-14.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael King
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLM Apollomics | Maintains: Buy | $1,100 → $650 | $16.27 | +3,895.08% | 4 | Apr 1, 2024 | |
| LTRN Lantern Pharma | Reiterates: Buy | $11 | $3.75 | +193.33% | 10 | Aug 10, 2023 | |
| BMEA Biomea Fusion | Reiterates: Buy | $32 | $1.22 | +2,522.95% | 11 | Jun 26, 2023 | |
| JSPR Jasper Therapeutics | Reiterates: Buy | $69 | $1.71 | +3,905.85% | 10 | Jun 12, 2023 | |
| COEP Coeptis Therapeutics Holdings | Assumes: Buy | $200 | $15.70 | +1,173.89% | 7 | May 25, 2023 | |
| HOWL Werewolf Therapeutics | Assumes: Buy | $8.3 | $0.95 | +772.12% | 6 | May 25, 2023 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Buy | $862 | $718.36 | +20.00% | 11 | May 1, 2023 | |
| EXEL Exelixis | Reiterates: Buy | $24 | $44.36 | -45.90% | 10 | Apr 28, 2023 | |
| AGEN Agenus | Reiterates: Buy | $166 | $3.93 | +4,123.92% | 8 | Mar 28, 2023 | |
| XNCR Xencor | Reiterates: Buy | $42 | $17.30 | +142.77% | 5 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $304 | $458.12 | -33.64% | 2 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $123 → $116 | $9.61 | +1,107.08% | 6 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $5.53 | +86.26% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $45.02 | -46.69% | 1 | Mar 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15,000 → $12,000 | $0.83 | +1,454,445.45% | 2 | Mar 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $46 | $44.41 | +3.58% | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $98 → $96 | $27.73 | +246.20% | 6 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $0.73 | +4,830.16% | 1 | Jan 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $31 | $38.77 | -20.04% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $33 → $36 | $901.17 | -96.01% | 2 | Nov 13, 2017 |
Apollomics
Apr 1, 2024
Maintains: Buy
Price Target: $1,100 → $650
Current: $16.27
Upside: +3,895.08%
Lantern Pharma
Aug 10, 2023
Reiterates: Buy
Price Target: $11
Current: $3.75
Upside: +193.33%
Biomea Fusion
Jun 26, 2023
Reiterates: Buy
Price Target: $32
Current: $1.22
Upside: +2,522.95%
Jasper Therapeutics
Jun 12, 2023
Reiterates: Buy
Price Target: $69
Current: $1.71
Upside: +3,905.85%
Coeptis Therapeutics Holdings
May 25, 2023
Assumes: Buy
Price Target: $200
Current: $15.70
Upside: +1,173.89%
Werewolf Therapeutics
May 25, 2023
Assumes: Buy
Price Target: $8.3
Current: $0.95
Upside: +772.12%
Regeneron Pharmaceuticals
May 1, 2023
Reiterates: Buy
Price Target: $862
Current: $718.36
Upside: +20.00%
Exelixis
Apr 28, 2023
Reiterates: Buy
Price Target: $24
Current: $44.36
Upside: -45.90%
Agenus
Mar 28, 2023
Reiterates: Buy
Price Target: $166
Current: $3.93
Upside: +4,123.92%
Xencor
Feb 24, 2023
Reiterates: Buy
Price Target: $42
Current: $17.30
Upside: +142.77%
Feb 24, 2023
Reiterates: Buy
Price Target: $304
Current: $458.12
Upside: -33.64%
Feb 24, 2023
Maintains: Buy
Price Target: $123 → $116
Current: $9.61
Upside: +1,107.08%
Dec 16, 2022
Initiates: Buy
Price Target: $10
Current: $5.53
Upside: +86.26%
Mar 23, 2022
Initiates: Buy
Price Target: $24
Current: $45.02
Upside: -46.69%
Mar 11, 2022
Maintains: Buy
Price Target: $15,000 → $12,000
Current: $0.83
Upside: +1,454,445.45%
Mar 8, 2022
Maintains: Buy
Price Target: $43 → $46
Current: $44.41
Upside: +3.58%
Mar 3, 2022
Maintains: Buy
Price Target: $98 → $96
Current: $27.73
Upside: +246.20%
Jan 10, 2022
Initiates: Buy
Price Target: $36
Current: $0.73
Upside: +4,830.16%
Nov 5, 2021
Maintains: Buy
Price Target: $25 → $31
Current: $38.77
Upside: -20.04%
Nov 13, 2017
Maintains: Market Outperform
Price Target: $33 → $36
Current: $901.17
Upside: -96.01%